On January 6, 2022 SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, reported that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will present during two virtual investor conferences in January (Press release, Scynexis, JAN 6, 2022, View Source [SID1234598332]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:

LifeSci Partners 11th Annual Corporate Access Event
Format: Virtual panel discussion with CEO and 1:1 meetings
Panel Title: The Best of Both Worlds – Defining Yourself When You Fit into More Than One Basket
Date and Time: Friday, January 7, at 10:00 a.m. ET
Registration link: LifeSci Partners Corporate Access Event 2022
H.C. Wainwright Bioconnect 2022 Virtual Healthcare Conference
Format: Virtual event with webcast of corporate update presentation by Dr. Taglietti
Date and Time: Presentation webcast will be available on-demand January 10-13 for event participants
Registration link: H.C. Wainwright Bioconnect 2022
The latest SCYNEXIS investor presentation can be found on the corporate website here.